

Psoriasis: Oral and Novel Biologics to Change Future Market Dynamic

<https://marketpublishers.com/r/P03DF86B59AEN.html>

Date: April 2012

Pages: 56

Price: US\$ 3,000.00 (Single User License)

ID: P03DF86B59AEN

Abstracts

In the report, “Psoriasis: Oral and Novel Biologics to Change Future Market Dynamic”; we are sharing our thoughts on some key drugs and targets in the pipeline for the treatment of Psoriasis. Successful launch of a few of these drugs could bring a dynamic change in the current market share of the approved drugs and validated targets.

Noteworthy amongst them are:

The Oral options- JAK inhibitors led by PFE’s Tofacitinib and CELG’s PDE4 inhibitor, Apremilast.

New or better biologics include IL12/23 inhibitors and IL-17/IL17A inhibitors

Unlike RA, Psoriasis treatment demands topical drug intervention and several of the oral drugs are being formulated to meet the need and proved an end to end solution. The aim is to fulfill the unmet need in Mild- moderate patients, TNF-non responders, and of course, affordability.

The report discusses the disease, pathophysiology, current treatment options, limitations and market potential and future growth in detail.

Competitive Landscape of the drugs in pipeline – Oral, Biologics, and Topical and the comparative efficacy safety data could provide insight on how this therapy treatment paradigm could unfold in the future and identify investment opportunities.

Upcoming milestones related to the drugs and companies mentioned are highlighted in the report to help you decide on the long and short term investment opportunity.

Contents

1. EXECUTIVE SUMMARY

2. WHAT IS THE UNMET NEED IN PSORIASIS?

- 2.1. Limited Options for Anti-TNF Non-Responders in Psoriasis
- 2.2. Limitations of Anti-TNFs
- 2.3. Scope for entrants with better efficacy and safety profiles
- 2.4. Specific unmet need and emerging therapies in PsO and PsA

3. EMERGING THERAPIES

- 3.1. Biologics/ Next-Generation Biologics for Psoriasis
 - 3.1.1. IL-12 and IL-23 Inhibitors
 - 3.1.2. Interleukin-17 (IL-17) And Receptor (IL-17RA)
 - 3.1.3. Other Targets
- 3.2. Oral treatments
 - 3.2.1. Targeting JAK-STATs
 - 3.2.2. Phosphodiesterases 4 (PDE4) Inhibitor
 - 3.2.3. Targeting Other Kinases
 - 3.2.4. Will the oral drugs being investigated in RA work for Psoriasis?
 - 3.2.5. Other Targets
- 3.3. Topical treatments

4. UPCOMING MILESTONES

5. MARKET OUTLOOK

- 5.1. Current market overview and Commercial potential of upcoming therapies

6. ETIOLOGY AND PATHOPHYSIOLOGY OF PSORIASIS

- 6.1. Types of Psoriasis
- 6.2. Psoriatic Arthritis (PsA) – Disease Overview
- 6.3. Assessment of PsA – Treatment Efficacy Tools
- 6.4. Aftermaths of PsA

7. CURRENT TREATMENT OPTIONS

- 7.1. Comparison of the current data with approved biologics/ other drugs for Psoriasis
- 7.2. Treatment guidelines and factors influencing drug selection

APPENDIX

Tables

TABLES

- 1 Approved/ Marketed Products
- 2A Psoriasis' Pipeline: Small Molecules – Oral
- 2B Psoriasis' Pipeline: Small Molecules – Topical
- 3 Psoriasis' Pipeline: Biologics
- 4 Select Late- & Mid-Stage Pipeline: Plaque Psoriasis
- 5 Select Late- & Mid-Stage Pipeline: Psoriatic Arthritis
- 6 Clinical Data Comparison: Plaque Psoriasis – Biologics
- 7A Tofacitinib: PASI Improvement From Baseline
- 7B Tofacitinib: Improvement In Quality-of-Life (QoL) Measures
- 8 Clinical Data Comparison: Plaque Psoriasis – Oral
- 9 Other Targets In Clinical Development For RA
- 10 Genes Associated With Psoriasis Susceptibility
- 11 Competitive Landscape: Plaque Psoriasis
- 12 Competitive Landscape: Psoriatic Arthritis
- 13 Distinct Features: Subtypes of PsA

Figures

FIGURES

- 1 The Structure And Function Of The Cytokines Il-12 And Il-23
- 2 PHOENIX 1 Clinical Data: PASI 75 Through Wk
- 3 Clinical Data: ACCEPT – Head-To-Head Trial
- 4 MK-3222 Neutralizes IL-23, Specifically
- 5 IL-17R Family Ligand–Receptor – Main Structural Features
- 6 IL-17-Induced Signaling Pathways
- 7 Regulation of JAK–STAT Signaling
- 8 ASP015K – Changes From Baseline In PASI At Day
- 9 PDE Inhibitors Crosstalk
- 10 AEB071 – PASI 75 Reduction Compared With Baseline
- 11 S1P Receptors As Barrier-Oriented Therapeutic Molecules
- 12 AN2728 – PhIIb (204 Study) Data
- 13 Psoriasis Treatment Ladder (Schematic)
- 14 Topical: Worldwide Market Share
- 15 Biologic - Psoriasis: US Market Share And Product Sales
- 16 US Psoriasis Market Estimation
- 17 Proposed Schema of The Evolution of A Psoriatic Lesion
- 18 Distribution of Psoriasis Severity
- 19 Use of Therapies Depending on The Disease Severity
- 20 Targeted Therapy Classification Based On Pathogenesis
- 21 Comparison of GRAPPA And AAD Treatment Guidelines

I would like to order

Product name: Psoriasis: Oral and Novel Biologics to Change Future Market Dynamic

Product link: <https://marketpublishers.com/r/P03DF86B59AEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P03DF86B59AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970